Agreement builds on the proven and successful collaboration of commercialization of FYB201, Formycon's biosimilar to Lucentis ® 2 (ranibizumab) in Europe The partnership broadens Teva's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback